

<sup>1</sup> A mathematical model for Zika virus  
<sup>2</sup> transmission with Optimal Control

<sup>3</sup> Santosh Kumar Sharma <sup>\*1</sup> and Nawin Kumar Agrawal<sup>2</sup>

<sup>4</sup> <sup>1</sup>Department of Mathematics, K. L. S. College, Nawada, Magadh University, Bodh  
<sup>5</sup> Gaya, Bihar-805110, India

<sup>6</sup> <sup>2</sup>Department of Mathematics, L N Mithila University, Darbhanga Bihar 846008,  
<sup>7</sup> India

<sup>8</sup> October 16, 2023

<sup>9</sup> **Abstract**

<sup>10</sup> In this research, we developed a mathematical model to study the co-  
<sup>11</sup> interaction of the Zika virus (a vector-borne disease). We qualitatively  
<sup>12</sup> analyzed the model and established the necessary conditions under which  
<sup>13</sup> disease-free and endemic equilibria are asymptotically stable. We qualita-  
<sup>14</sup> tively analyzed the model and established the necessary conditions under  
<sup>15</sup> which disease-free and endemic equilibria are asymptotically stable. There  
<sup>16</sup> are only two possible equilibrium points in our system, two of which are  
<sup>17</sup> endemic and one of which is devoid of disease. The disease-free equilib-  
<sup>18</sup> rium is shown by the theoretical study to be both locally and globally  
<sup>19</sup> asymptotically stable if the basic reproduction number is less than one.  
<sup>20</sup> The most sensitive factors of the analyzed Zika model are the number  
<sup>21</sup> of times susceptible (infected) individuals were bitten by susceptible (in-  
<sup>22</sup> fected) mosquitoes, the host population's awareness rate, and the recovery  
<sup>23</sup> rates of susceptible (infected) humans. The World Health Organisation  
<sup>24</sup> has classified the current Zika virus (ZIKV) pandemic as a worldwide  
<sup>25</sup> public health emergency. Concerns include the lack of effective diagno-  
<sup>26</sup> stic tests and vaccinations, the wide geographic range of mosquito species  
<sup>27</sup> that can spread the virus, and the lack of population immunity in recently  
<sup>28</sup> impacted nations.

<sup>29</sup> **Keywords:** Zika virus, Reproduction number, Optimal control, Stability anal-  
<sup>30</sup> ysis, equilibrium point.

<sup>31</sup> **1 Introduction**

<sup>32</sup> Zika is a mosquito-borne virus that was initially discovered in a Rhesus macaque  
<sup>33</sup> monkey in Uganda in 1947. Infection and sickness in people were then discovered

---

<sup>\*</sup>Corresponding author. Email: santoshmumath@gmail.com

34 in other African nations in the 1950s. Between the 1960s and the 1980s, isolated  
35 cases of human infections were reported from Asia and Africa. However, since  
36 2007, epidemics of the Zika virus infection have been documented in Africa,  
37 the Americas, Asia, and the Pacific. When the Zika virus first emerged in the  
38 Americas, a link between infection and microcephaly (a smaller-than-normal  
39 head size) was first noticed.

40 The WHO declared a Public Health Emergency of International Concern  
41 (PHEIC) in relation to microcephaly, other neurological disorders, and the Zika  
42 virus as soon as the link between the Zika virus and congenital malformations  
43 was confirmed. In India, Zika virus epidemic activity was discovered in 2021.  
44 Although 89 nations and territories have yet to report evidence of Zika virus  
45 infection brought on by mosquitoes, worldwide surveillance is still insufficient.  
46 Symptoms of the Zika virus in most infected individuals are rare. If they develop,  
47 they often begin 3–14 days after infection, are minor in nature, include rash,  
48 fever, conjunctivitis, muscle and joint pain, malaise, and headache, and last  
49 2–7 days on average. In tropical and subtropical areas, Aedes (Stegomyia)  
50 genus mosquitoes, especially Aedes aegypti, are the major vectors of Zika virus  
51 transmission.

52 In the course of the day, Aedes mosquitoes typically bite. Along with trans-  
53 mitting urban yellow fever, these mosquitoes also spread dengue and chikun-  
54 gunya. People who experience rashes, fevers, or joint discomfort should obtain  
55 plenty of rest, drink lots of water, and use antipyretics and/or analgesics to  
56 relieve their symptoms. Patients should seek medical attention and counseling  
57 if their symptoms get worse. Pregnant women who live in Zika transmission  
58 regions or who exhibit signs of the virus should consult a doctor for clinical  
59 treatment, laboratory testing, education, and other services. Protection against  
60 mosquito bites throughout the day and early evening is a vital step in avoiding  
61 Zika virus infection, especially among pregnant women, women who are trying  
62 to get pregnant, and young children. Examples of personal safety precautions  
63 include dressing in clothing that covers as much of the body as possible and is  
64 ideally light in color;

65 Recent studies, how the human and mosquito populations how the virus  
66 spreads. The study by Ali et al [2], According to the studies by Gonalez-Parra  
67 Gilberto, et al [9], The Zika virus can be contained more effectively with the  
68 help of educational programs and pesticide use. The study by Bernhauerov  
69 et al [4], provided a numerical characterization of in vitro ZIKV infection and  
70 contributed to a better understanding of the dynamics of ZIKV-host cell in-  
71 teractions. A mathematical model and cost-effectiveness analysis to compare  
72 different control strategies and emphasize the need for accurate implementation  
73 of optimal control measures. by the studies, Wanget al. [18], In the study of  
74 Aldila et al. [1], it was discovered that when  $R_0$  is greater than 1, a local asymptote,  
75 or endemic equilibrium point, exists. Reducing the impact of Zika on the  
76 neighborhood may be possible with the addition of a class of asymptomatic car-  
77 riers and the use of control measures. The studies of Khan et al. [11], According  
78 to Bonyah et al. [6], studied the best strategies to control a co-infection model  
79 while using the center manifold theory to examine the dynamics of a system.

80 Transmission dynamics between humans and mosquitoes, the impact of vaccination  
81 and the effectiveness of different control strategies. In the study by Sharma  
82 et al [16], The ideal control system employing prevention, treatment, and pesti-  
83 cide spraying is determined by the stability analysis of the model's fixed points.  
84 By the studies, Alzahrani et al [3], By the studies, Biswas et al. [5] provide cal-  
85 culations and analysis to comprehend the dynamics of the virus in populations  
86 of both humans and mosquitoes. Rezapour et al. [15] found that the fractional-  
87 order Caputo derivative is what transmits the Zika virus between people and  
88 mosquitoes. According to the study, Nwalozie et al. [13] better preventative,  
89 control, and management measures are needed to decrease the consequences of  
90 the Zika virus on world health. Studies by Mello et al. [7] show that baculovirus  
91 expression technology is used in insect cell cultures to create vaccines against  
92 arboviruses, such as ZIKV.

93 These techniques are being used by WHO to stop the Zika virus. who It  
94 assists nations in confirming epidemics, offers technical assistance and direction  
95 for the efficient control of disease outbreaks brought on by mosquitoes, looks into  
96 the development of new tools, such as pesticide products and application tech-  
97 nology, develops evidence-based strategies for managing attacks and solutions,  
98 and assists nations in confirming epidemics with the assistance of its network of  
99 cooperating laboratories.

100 Two areas where mathematical models have a big impact are the dynamics  
101 of infectious diseases and the development of improved techniques to halt their  
102 spread in the future. Using mathematical models, the dynamic is anticipated,  
103 and this helps to create more efficient techniques for stopping its spread in the  
104 future.

105 The numerical findings of our study were produced using built-in MATLAB  
106 functions since we were more concerned with analyzing the qualitative dynam-  
107 ical behaviors of the model under discussion than with the precision, rate of  
108 convergence, etc. of the generated numerical solutions. Additionally, we have  
109 created an optimum control issue for the system, where the objectives are to  
110 reduce immunization and boost revenue.

111 In this study, we proposed epidemiological models for the Zika virus that  
112 consider the virus' antigenic changes. In the models for transmission, specifics  
113 on changes to the amino acid sequences of the HA proteins at epitope regions  
114 were included. First, using the sequencing data, we calculated the rate of time-  
115 varying antigenic change for each Zika virus subtype. Finally, we demonstrated  
116 how changes in viral antigenicity may drastically influence the dynamics of Zika  
117 virus transmission at the population level. In light of this, we suggested epi-  
118 demiological models for the Zika viruses. We therefore proposed epidemiological  
119 models for the Zika virus.

120 The article is organized as follows. In part 2, which is the section after this  
121 one, we create the mathematical model. Fundamental characteristics like well-  
122 posedness, nonnegativity, boundedness, etc. are examined in Section 3. Analysis  
123 of equilibrium and stability is discussed in Section 4. Section 5 presents the topic  
124 of best control. The discussion in Section 6 concludes the essay.




Figure 1: Schematic diagram of the model (1)

## <sup>125</sup> 2 Formulation of Zika Virus Epidemic Model

<sup>126</sup> The transmission model with media coverage is given by the following deter-  
<sup>127</sup> ministic system of nonlinear ordinary differential equations

$$\begin{aligned} \frac{dS}{dt} &= \Lambda + \omega V - \frac{\beta SI}{1+pI} - (\mu + \theta)S, \\ \frac{dI}{dt} &= \frac{\beta SI}{1+pI} + \frac{\beta' VI}{1+pI} - (\mu + \alpha)I, \\ \frac{dV}{dt} &= \theta S - (\mu + \omega)V - \frac{\beta' VI}{1+pI}, \\ \frac{dR}{dt} &= \alpha I - \mu R. \end{aligned} \quad (1)$$

<sup>128</sup> where the initial conditions are

$$S = S_0, \quad I = I_0, \quad V = V_0, \quad R = R_0. \quad (2)$$

<sup>129</sup> In this model,  $\Lambda$  is the constant production,  $\omega$  is the [],  $\beta$  is Transmission rate,  
<sup>130</sup>  $p$  is Haf saturation constant,  $\mu$  is Death rate,  $\theta$  is Rate of vacillation,  $\alpha$  is  
<sup>131</sup> Rate of infected, and  $\beta'$  is Disseases transmission after vacillation. The schematic  
<sup>132</sup> explanation of our proposed model is displayed in Figure 1. The values of the  
<sup>133</sup> parameters of the model (1) are given in Table (1).

## <sup>134</sup> 3 Stability of the equilibrium states

<sup>135</sup> (A) The disease-free equilibrium of the system (1) is given by

$$E^0 = (S^0, I^0, V^0, R^0) = \left( \frac{\Lambda(\mu + \omega)}{\mu(\mu + \omega + \theta)}, 0, \frac{\Lambda\theta}{\mu(\mu + \omega + \theta)}, 0 \right). \quad (3)$$

<sup>136</sup> (B) The endemic equilibrium of the system (1) is given by

$$E^* = (S^*, I^*, V^*, R^*),$$

<sup>137</sup> It satisfies  $S^* > 0$ ,  $I^* > 0$ ,  $V^* > 0$ ,  $R^* > 0$  and

$$\begin{aligned} S^* &= \frac{Y_1 - (\Lambda + \omega V^*)}{(\mu + \theta)}, \\ I^* &= \frac{(Y_1 + Y_2)}{(\mu + \alpha)}, \\ V^* &= \frac{(\theta S^* - Y_2)}{(\mu + \alpha)}, \\ R^* &= \frac{\alpha I^*}{\mu}. \end{aligned} \tag{4}$$

<sup>138</sup> where,

$$Y_1 = \frac{\beta S^* I^*}{(1 + pI^*)} \text{ and } Y_2 = \frac{\beta' V^* I^*}{(1 + pI^*)}.$$

<sup>139</sup> Substituting the above into the second equation at equilibrium will yield the  
<sup>140</sup> expression for  $I$  after some rearrangement. For illustration,

## <sup>141</sup> 4 Basic reproduction number of the model

<sup>142</sup> The local stability of the system  $E^0$  is governed by the basic reproduction num-  
<sup>143</sup> ber  $R_0 < 1$ . The basic reproduction number is the average number of new  
<sup>144</sup> secondary infections in entirely susceptible Zika virus produced by a single in-  
<sup>145</sup> fected Zika virus. With the help of the next generation method [17], we can  
<sup>146</sup> calculate the basic reproduction number. For this method, we consider the  
<sup>147</sup> model variables in such a manner that the compartments reflect only infected  
<sup>148</sup> individuals. By this assumption, we have  $y = (S, I, V, R)$ , where  $I$  are the  
<sup>149</sup> infected compartments. Furthermore,  $\mathcal{G}_H$  denotes the set of all infection-free  
<sup>150</sup> states—that is,

$$\mathcal{X}_H = \{X \geq 0 : X_i, i = 1, 2\}. \tag{5}$$

<sup>151</sup> System (1) is rewritten as

$$X'_i = h_i(X) = \mathcal{F}_i(X) - \mathcal{G}_i(X), i = 1, 2, \tag{6}$$

<sup>152</sup> where  $\mathcal{F}_i(X)$  describes the rate of appearance of new infections in compartment  
<sup>153</sup>  $i$ . Moreover,

$$\mathcal{Y}_i(X) = \mathcal{G}_i^-(X) - \mathcal{G}_i^+(X), \tag{7}$$

<sup>154</sup>  $\mathcal{Y}_i^+(X)$  is the transmission rate into the compartment  $i$ , and  $\mathcal{Y}_i^-(X)$  is the  
<sup>155</sup> rate of transmission out of this compartment. The subsequent norms are to be  
<sup>156</sup> modeled.

157 (B<sub>1</sub>)  $\mathcal{F}_i(X) \geq 0$ ,  $\mathcal{G}_i^-(X) \geq 0$ ,  $\mathcal{G}_i^+(X) \geq 0$ , for any  $X \geq 0$ ;

158

159 (B<sub>2</sub>) If  $X_i = 0$ , then  $\mathcal{G}_i^- = 0$ ;

160

161 (B<sub>3</sub>)  $\mathcal{F}_i = 0$ , for  $i = 2$ ;

162

163 (B<sub>4</sub>) If  $X \in \mathcal{X}_H$ , then  $\mathcal{F}_i(X) = 0$ ,  $\mathcal{G}_i^+(X) = 0$ , for  $i = 1, 2$ ;

164

165 (B<sub>5</sub>) For the disease-free equilibrium (DFE)  $X_0$ , the Jacobi matrix  $Dh(X_0)$   
166 constrained to the subspace  $h = 0$  has all negative eigenvalues.

167 To formulate the next generation matrix  $FG^{-1}$  [17] from matrices of partial  
168 derivatives of  $\mathcal{F}_i$  and  $\mathcal{G}_i$ . Specifically,

$$F = \left[ \frac{\partial \mathcal{F}_i(X_0)}{\partial X_j} \right], \quad G = \left[ \frac{\partial \mathcal{G}_i(X_0)}{\partial X_j} \right], \quad (8)$$

169 where  $i, j = 1, 2$ . Here,  $F$ ,  $G$  are two-dimensional squared matrices and  $R_0 =$   
170  $\varrho(FG^-)$  ( $\varrho$  denotes a spectral radius of the matrix). For model (1), we have

$$\mathcal{F} = \begin{pmatrix} \frac{\beta SI}{1+pI} + \frac{\beta' VI}{(1+pI)} \\ 0 \end{pmatrix}, \quad \mathcal{G} = \begin{pmatrix} (\mu + \alpha)I \\ -\alpha I + \mu R \end{pmatrix}. \quad (9)$$

171 Next, we are setting that the entry-wise non-negative new infection matrix  
172 is  $F$ . Let the non-singular Metzler matrix [12] define the transitions of Zika  
173 virus infection between the infection compartments and the matrices, which are  
174 given as follows.

$$F = \begin{pmatrix} \frac{\beta S}{(1+pI)^2} + \frac{\beta' V}{(1+pI)^2} & 0 \\ 0 & 0 \end{pmatrix}, \quad G = \begin{pmatrix} \mu + \alpha & 0 \\ -\alpha & \mu \end{pmatrix},$$

$$G^{-1} = \begin{pmatrix} \frac{1}{(\mu+\alpha)} & 0 \\ \frac{\alpha}{\mu(\mu+\alpha)} & \frac{1}{\mu} \end{pmatrix}.$$

175 We observe that  $G^{-1}$  is also an entry-wise non-negative matrix and thus  
176  $FG^{-1}$  is an entry-wise non-negative next-generation matrix showing the ex-  
177 pected number of new infections which is given by

$$\begin{aligned} FG^{-1} &= \begin{bmatrix} \frac{\beta S}{(1+pI)^2} + \frac{\beta' V}{(1+pI)^2} & 0 \\ 0 & 0 \end{bmatrix} \times \begin{bmatrix} \frac{1}{(\mu+\alpha)} & 0 \\ \frac{\alpha}{\mu(\mu+\alpha)} & \frac{1}{\mu} \end{bmatrix}, \\ &= \begin{bmatrix} \frac{\beta S + \beta' V}{(1+pI)^2(\mu+\alpha)} & 0 \\ 0 & 0 \end{bmatrix}. \end{aligned} \quad (10)$$

Table 1: Parameters and their associated sensitivity indices along with the relative percentage impact on the threshold quantity ( $R_0$ )

Parameter	Definition	Value	Reference
$\Lambda$	Birth rate		
$\omega$			
$\beta$	Transmission rate		
$p$	Haf sauration costant		
$\mu$	Death rate		
$\theta$	Rate of vacillation		
$\alpha$	Rate of infected		
$\beta'$	Disseases transmission after vacillation		

Using the spectral radius of the next-generation matrix [10, 17], for the system (1), we find the basic reproduction number  $R_0$ , which is the largest eigenvalue of  $FG^{-1}$  at  $E^0$ . Thus,

$$\begin{aligned} R_0 &= \frac{\beta S + \beta' V}{(\mu + \alpha)}, \\ &= \frac{\beta S \mu (\mu + \omega + \theta) + \beta' \Lambda \theta}{\mu (\mu + \alpha) (\mu + \omega + \theta)}. \end{aligned} \quad (11)$$

**Theorem 1.** *The system (1) describes the spreading kinetics of Zika virus infection, which has a threshold parameter basic reproduction number  $R_o = \frac{\beta S \mu (\mu + \omega + \theta) + \beta' \Lambda \theta}{\mu (\mu + \alpha) (\mu + \omega + \theta)}$ . at  $E^0$ . For  $R_0 > 1$ , the system (1) has a unique positive endemic steady state.*

## 5 Local stability of the disease-free equilibrium

**Theorem 2.** *The disease-free equilibrium  $E^0$  is locally asymptotically stable if  $R_0 < 1$ , and unstable if  $R_0 > 1$ .*

*Proof.* The Jacobian of the system (1) evaluated at  $E^0$  is given by

$$J_{E^0} = \begin{pmatrix} -(\mu + \theta) & -\beta S & \omega & 0 \\ 0 & \beta S + \beta' V - (\mu + \alpha) & 0 & 0 \\ \theta & -\beta' V & -(\mu + \omega) & 0 \\ 0 & \alpha & 0 & -\mu \end{pmatrix}. \quad (12)$$

Here the eigenvalues are  $[\lambda = -\mu, \{(\beta S + \beta' V) - (\mu + \alpha)\}]$  and the other two eigenvalues are determined from the given equation

$$\begin{vmatrix} -(\mu + \theta) - \lambda & \omega \\ \theta & -(\mu + \omega) - \lambda \end{vmatrix} = 0 \quad (13)$$

<sup>191</sup> and the characteristic equation for (13) is

$$A_0\lambda^2 + A_1\lambda + A_2\lambda = 0. \quad (14)$$

<sup>192</sup> where,

$$A_0 = 1 > 0, \quad A_1 = (\omega + \theta + 2\mu), \quad A_2 = (\mu^2 + \mu\theta + \mu\omega).$$

<sup>193</sup> Now, it is easy to note that  $A_0 \geq 0$ , and  $A_1 > 0$ . If  $A_0 > 0$ , then all the  
<sup>194</sup> roots of Equation (4) will be negative (Section 3.3 in [10]). If  $A_2 > 0$ , then we  
<sup>195</sup> have threshold criteria to determine the stability condition at the infection-free  
<sup>196</sup> point  $E^0$ . We have the condition  $\mu_1 + 2\frac{p\hat{H}_S}{H_T} < \nu < \frac{\mu_2\mu_3}{\beta_1\hat{H}_S}$ , which implies that  
<sup>197</sup>  $R_0 < 1$  and results in the eradication of infection.  $\square$

## <sup>198</sup> 5.1 Local stability of the endemic equilibrium:

<sup>199</sup> **Theorem 3.** *The system (1) around  $E^*$  is locally asymptotically stable (LAS)  
<sup>200</sup> if  $R_0 > 1$ .*

<sup>201</sup> *Proof.* We already established that the equilibrium  $E^*$  is feasible when  $R_0 > 1$ .  
<sup>202</sup> Now, the Jacobi matrix around  $E^*$  is

$$|J_{E^*} - \lambda| = \begin{pmatrix} a_{11} - \lambda & a_{12} & a_{13} & 0 \\ a_{21} & a_{22} - \lambda & 0 & 0 \\ a_{31} & a_{32} & a_{33} - \lambda & 0 \\ 0 & a_{42} & 0 & a_{44} - \lambda \end{pmatrix}. \quad (15)$$

<sup>203</sup> where,

$$\begin{aligned} a_{11} &= -\frac{\beta I}{(1+pI)} - (\mu + \theta), \quad a_{12} = -\frac{\beta S}{(1+pI)^2}, \\ a_{21} &= \frac{\beta I}{(1+pI)}, \quad a_{22} = \frac{\beta S + \beta' V}{(1+pI)^2} - (\mu + \alpha), \\ a_{32} &= -\frac{\beta' V}{(1+pI)^2}, \quad a_{33} = -(\mu + \omega) - \frac{\beta' I}{(1+pI)}, \\ a_{13} &= \omega, \quad a_{31} = \theta, \quad a_{42} = \alpha, \quad a_{44} = \mu. \end{aligned}$$

<sup>204</sup> At  $E^*$ , the characteristic equation is

$$\lambda^4 - x_1\lambda^3 + x_2\lambda^2 + x_3\lambda^+x_4\lambda^0 = 0. \quad (16)$$

<sup>205</sup> where,

$$\begin{aligned} x_1 &= (a_{33} + a_{44} + a_{11} + a_{22}), \\ x_2 &= (a_{33}a_{44} + a_{11}a_{33} + a_{22}a_{44} + a_{11}a_{22}), \\ x_3 &= (a_{33}a_{44} - a_{11}a_{22}a_{33} - a_{11}a_{22}a_{44}), \\ x_4 &= (a_{11}a_{22}a_{33}a_{44}). \end{aligned}$$

<sup>206</sup> By the Routh-Hurwitz criteria at the endemic equilibrium  $E^*$ , the system (1)  
<sup>207</sup> is LAS if  $R_0 > 1$ .  $\square$

<sup>208</sup> **6 Global Stability**

<sup>209</sup> **Theorem 4.** *The system is globally asymptotically stable (GAS) when  $R_0 < 0$ .*

<sup>210</sup> *Proof.* We consider the Lyapunov function as follows:

$$L_1 = \xi_1 I + \xi_2 V + \xi_3 R. \quad (17)$$

<sup>211</sup> Differentiating the Lyapunov function  $L_1(17)$  with respect to t, we find

$$\begin{aligned} \frac{dL_1}{dt} &= \xi_1 \frac{dI}{dt} + \xi_2 \frac{dV}{dt} + \xi_3 \frac{dR}{dt} \\ &= \xi_1 \left[ \frac{\beta SI}{(1+pI)} + \frac{\beta' VI}{(1+pI)} - (\mu + \alpha)I \right] + \xi_2 (\alpha I - \mu R) \end{aligned} \quad (18)$$

<sup>212</sup> When  $R_0 < 1$ , we have  $\frac{dL_1}{dt} < 0$  and  $\frac{dL_1}{dt} = 0$  implies that  $R = 0$ . From the  
<sup>213</sup> model (1), we can say that  $I = 0$  when  $R = 0$  in the limit  $t \rightarrow 0$ . Hence, ac-  
<sup>214</sup> cording to the Lyapunov–LaSalle theorem, the system is globally asymptotically  
<sup>215</sup> stable when  $R_0 < 1$ . This completes the proof.  $\square$

<sup>216</sup> **Theorem 5.** *The endemic equilibrium  $E^*$  is globally asymptotically stable (GAS)  
<sup>217</sup> if  $R_0 > 1$ .*

<sup>218</sup> *Proof.* Let us consider the Dulac function:

$$D(S, I, V, R) = \frac{1}{(S I V R)}, \quad (19)$$

<sup>219</sup> and denote the R.H.S of equations in the system (1) as

$$\begin{aligned} Z_1 &= \Lambda + \omega V - \frac{\beta SI}{1+pI} - (\mu + \theta)S, \\ Z_2 &= \frac{\beta SI}{1+pI} + \frac{\beta' VI}{1+pI} - (\mu + \alpha)I, \\ Z_3 &= \theta S - (\mu + \omega)V - \frac{\beta' VI}{1+pI}, \\ Z_4 &= \alpha I - \mu R. \end{aligned} \quad (20)$$

<sup>220</sup> Then, from (20), we have

$$\begin{aligned} \frac{\partial(DZ_1)}{\partial S} &= -\frac{1}{S^2 IV R} \left[ \Lambda + \omega V - \frac{\beta SI}{(1+pI)} - (\mu + \theta)S \right] \\ &\quad + \frac{1}{SIVR} \left[ -\frac{\beta I}{(1+pI)} - (\mu + \theta) \right], \\ &= -\frac{(\Lambda + \omega V)}{S^2 IV R} < 0, \end{aligned} \quad (21)$$

$$\begin{aligned}
\frac{\partial(DZ_2)}{\partial I} &= -\frac{1}{SI^2VR} \left[ \frac{\beta SI + \beta' VI}{(1+pI)} - (\mu + \alpha)I \right] \\
&\quad + \frac{1}{SIVR} \left[ \frac{\beta S + \beta' V}{(1+pI)^2} - (\mu + \alpha) \right], \\
&\quad - \frac{p(\beta S + \beta' V)}{SVR(1+pI)^2} < 0,
\end{aligned} \tag{22}$$

$$\begin{aligned}
\frac{\partial(DZ_3)}{\partial I} &= -\frac{1}{SIV^2R} \left[ \theta S - (\mu + \omega)V - \frac{\beta' VI}{(1+pI)} \right] \\
&\quad + \frac{1}{SIVR} \left[ -(\mu + \omega) - \frac{\beta' I}{(1+pI)} \right], \\
&\quad - \frac{\theta S}{SIV^2R} < 0,
\end{aligned} \tag{23}$$

$$\begin{aligned}
\frac{\partial(DZ_4)}{\partial I} &= -\frac{1}{SIVR^2} (\alpha I - \mu R) + \frac{1}{SIVR} (-\mu), \\
&\quad - \frac{\alpha I}{SIVR^2} < 0.
\end{aligned} \tag{24}$$

<sup>221</sup> From the inequalities (21)-(24), we find

$$\frac{\partial(DZ_1)}{\partial S} + \frac{\partial(DZ_2)}{\partial I} + \frac{\partial(DZ_3)}{\partial V} + \frac{\partial(DZ_4)}{\partial R} < 0. \tag{25}$$

<sup>222</sup> Thus, every positive solution of the system (1) tends to the endemic equilibrium  
<sup>223</sup>  $E^*$  when  $R_0 > 1$ . According to the Dulac–Bendixson theorem, there exists no  
<sup>224</sup> periodic orbit for (1), and hence the system is globally asymptotically stable for  
<sup>225</sup>  $E^*$ .  $\square$

## <sup>226</sup> 7 The optimal control model

<sup>227</sup> Control theoretic study plays a pivotal role in the minimization of different in-  
<sup>228</sup> fectious diseases. We use optimization techniques to develop an optimal control  
<sup>229</sup> mechanism that minimizes the transmission of the novel Zika virus. We have in-  
<sup>230</sup> corporated the combination of two control parameters/variables as symbolized  
<sup>231</sup> by  $u(t)$  and define it as  $u(t) = \{u_1(t), u_2(t)\}$ . Physically or biologically these  
<sup>232</sup> control measures represent the reverse transcript inhibitor, and the control min-  
<sup>233</sup> imizing the reservoir contribution to the virus. We place the control functions

<sup>234</sup> into the model (1) which leads to the following state system:

$$\begin{aligned}\frac{dS}{dt} &= \Lambda + \omega V - \frac{\beta SI}{\{1 + (1 - u_2)pI\}} - \{\mu + (1 - u_1)\theta\}S, \\ \frac{dI}{dt} &= \frac{\beta SI}{\{1 + (1 - u_2)pI\}} + \frac{\beta' VI}{\{1 + (1 - u_2)pI\}} - (\mu + \alpha)I, \\ \frac{dV}{dt} &= (1 - u_1)\theta S - (\mu + \omega)V - \frac{\beta' VI}{\{1 + (1 - u_2)pI\}}, \\ \frac{dR}{dt} &= \alpha I - \mu R.\end{aligned}\tag{26}$$

<sup>235</sup> where the initial conditions are

$$S = S_0, \quad I = I_0, \quad V = V_0, \quad R = R_0.\tag{27}$$

<sup>236</sup> We define the objective cost function as follows:

$$J[u, x] = \int_0^{t_f} (Au_1^2 + Bu_2^2 + CI^2) dt\tag{28}$$

<sup>237</sup> Here the main aim is to minimize the cost function subject to the state system  
<sup>238</sup> (26).

<sup>239</sup> In the objective function described by (28), where  $x = (S, I, V, R)$  and  
<sup>240</sup> A, B and C, are the positive constants called weight constants. The weight-  
<sup>241</sup> ing constants I are the relative costs of infection and virus, while A and B are  
<sup>242</sup> the weighting constants that measure the associated cost of the control variables  
<sup>243</sup>  $u_1(t)$  and  $u_2(t)$  respectively.

<sup>244</sup> We have to find the optimal control function represented by  $(u_1^*, u_2^*)$  such  
<sup>245</sup> that

$$J(u_1^*, u_2^*) = \min\{J(u_1, u_2), u_i \in \mathcal{U}, \text{ for } i = 1, 2\},\tag{29}$$

<sup>246</sup> subject to the state system (26) and the control set  $\mathcal{U}$  is described as:

$$\mathcal{U} = \{(u_1, u_2) : u_i \text{ is Lebesgue measurable and } 0 \leq u_i(t) \leq 1, i = 1, 2\}.\tag{30}$$

<sup>247</sup> where  $\mathcal{U}$  is the control set. The basic concept of an optimal control problem  
<sup>248</sup> is to prove the existence of optimal control through an optimality system [14].  
<sup>249</sup> Here we prove the existence condition of optimal control problem by using the  
<sup>250</sup> approach of Fleming and Rishel [8].

<sup>251</sup> Further to proceed, the existence of such control measures variables will be  
<sup>252</sup> shown. The existence of a system is subjected to the boundedness of the controls  
<sup>253</sup> as well as Lebesgue measurable, and the initial data non-negativity. Thus the  
<sup>254</sup> control problem may take the form:

$$\frac{dX}{dt} = PX + Q(X).\tag{31}$$

<sup>255</sup> where  $X = (S, I, V, R)'$ , and the matrices  $P$  and  $Q(X)$  respectively containing  
<sup>256</sup> the linear and nonlinear bounded coefficients are given by the following:

257 **Theorem 6.** *There exists an optimal solution  $u^* = (u_1^*, u_2^*) \in \mathcal{U}$  to the control*  
258 *problem (42).*

259 *Proof.* Clearly, the state and control variables have non-negative values. Furthermore,  
260 the set of control  $\mathcal{U}$  is closed and convex. Moreover, the boundedness  
261 of the control system leads to its compactness. The integral functional (28) is  
262 also convex. Therefore, optimal controls exist.  $\square$

## 263 7.1 Methodology

264 Let the control input  $u^*(t)$  denote the quantity of the drug dose at time  $t$ . The  
265 cost function (28) subject to the system of ODE (26) represents the necessary  
266 conditions for which an optimal control and corresponding states must sat-  
267 isify Pontryagin's Maximum Principle. To determine the optimal control  $u_1^*(t)$   
268 and  $u_2^*(t)$ , we use Pontryagin's maximum principle [14]. With the aid of this  
269 principle, we change the system (42) and the cost function (28) into a mini-  
270 mizing problem by constructing the Hamiltonian function  $H$  with respect to  
271  $(u_1(t), u_2(t))$ .

272 We find the optimal values to the problem described by (28) subject to  
273 the control system (26). For that, the Lagrangian, as well as the Hamiltonian  
274 associated with the control problem, will be defined. Therefore, we take the  
275 state variable  $x$  and control variable  $u$  to define the Lagrangian ( $\mathcal{L}$ ) as

$$\mathcal{L} = Au_1^2 + Bu_2^2 + CI. \quad (32)$$

276 Using the adjoint variables together with the state variables, the Hamiltonian  
277 is constructed as follows:

$$\begin{aligned} \mathcal{H} = & Au_1^2 + Bu_2^2 + CI^2 \\ & + \lambda_1 \left[ \Lambda + \omega V - \frac{\beta SI}{\{1 + (1 - u_2)pI\}} - \{\mu + (1 - u_1)\theta\}S \right] \\ & + \lambda_2 \left[ \frac{\beta SI}{\{1 + (1 - u_2)pI\}} + \frac{\beta' VI}{\{1 + (1 - u_2)pI\}} - (\mu + \alpha)I \right] \\ & + \lambda_3 \left[ (1 - u_1)\theta S - (\mu + \omega)V - \frac{\beta' VI}{\{1 + (1 - u_2)pI\}} \right]. \\ & + \lambda_4(\alpha I - \mu R). \end{aligned} \quad (33)$$

278 Here,  $\xi_i$ ,  $i = 1, 2, 3, 4$  denote the adjoint variables,  $P$  and  $Q$  are the weight  
279 constants, and  $A$  represents the penalty multiplier.

280 From (33), we have

$$\begin{aligned}
\frac{\partial \mathcal{H}}{\partial S} &= \frac{\beta I}{\{1 + (1 - u_2)pI\}} (\lambda_2 - \lambda_1) - \lambda_1 \{\mu + (1 - u_1)\theta\} + \lambda_3(1 - u_1)\theta, \\
\frac{\partial \mathcal{H}}{\partial I} &= 2CI + \frac{\beta S}{\{1 + (1 - u_2)pI\}^2} (\lambda_2 - \lambda_1) + \frac{\beta' V}{\{1 + (1 - u_2)pI\}^2} (\lambda_2 - \lambda_3) - \lambda_2(\mu + \alpha) + \lambda_4(\alpha), \\
\frac{\partial \mathcal{H}}{\partial V} &= \lambda_1\omega + \frac{\beta' I}{\{1 + (1 - u_2)pI\}} (\lambda_2 - \lambda_3) - \lambda_3(\mu + \omega), \\
\frac{\partial \mathcal{H}}{\partial R} &= \lambda_4(-\mu), \\
\frac{\partial \mathcal{H}}{\partial u_1} &= 2Au_1 + \theta S(\lambda_1 - \lambda_3), \\
\frac{\partial \mathcal{H}}{\partial u_2} &= 2Bu_2 + \frac{\beta SpI^2}{\{1 + (1 - u_2)pI\}^2} (\lambda_2 - \lambda_1) + \frac{\beta' VpI^2}{\{1 + (1 - u_2)pI\}^2} (\lambda_2 - \lambda_3).
\end{aligned} \tag{34}$$

<sup>281</sup> According to Pontryagin's minimum principle, the adjoint variables satisfy,

$$\frac{d\xi}{dt} = -\frac{\partial \mathcal{H}}{\partial x}. \tag{35}$$

<sup>282</sup> Therefore, using (35), the adjoint system evaluated at optimal controls input  
<sup>283</sup>  $(u_1(t), u_2(t))$  and corresponding to the model state variables  $(S, I, V, R)$  is ob-  
<sup>284</sup> tained as:

$$\begin{aligned}
\frac{d\lambda_1}{dt} &= - \left[ \frac{\beta I}{\{1 + (1 - u_2)pI\}} (\lambda_2 - \lambda_1) - \lambda_1 \{\mu + (1 - u_1)\theta\} + \lambda_3(1 - u_1)\theta \right], \\
\frac{d\lambda_2}{dt} &= - \left[ 2CI + \frac{\beta S}{\{1 + (1 - u_2)pI\}^2} (\lambda_2 - \lambda_1) + \frac{\beta' V}{\{1 + (1 - u_2)pI\}^2} (\lambda_2 - \lambda_3) - \lambda_2(\mu + \alpha) + \lambda_4(\alpha) \right], \\
\frac{d\lambda_3}{dt} &= - \left[ \lambda_1\omega + \frac{\beta' I}{\{1 + (1 - u_2)pI\}} (\lambda_2 - \lambda_3) - \lambda_3(\mu + \omega) \right], \\
\frac{d\lambda_4}{dt} &= - [\lambda_4(-\mu)].
\end{aligned} \tag{36}$$

<sup>285</sup> The transversality conditions are  $\lambda_1(t_f) = 0$ ,  $\lambda_2(t_f) = 0$ ,  $\lambda_3(t_f) = 0$ ,  $\lambda_4(t_f) =$   
<sup>286</sup> 0. Now Pontryagin's Maximum Principle [14] states that the unconstrained op-  
<sup>287</sup> timal control  $u^*(t)$  satisfies

$$\frac{\partial H}{\partial u(t)} = 0. \tag{37}$$

<sup>288</sup> This gives,

$$\begin{aligned}
\frac{\partial \mathcal{H}}{\partial u_1} &= 2Au_1 + \theta S(\lambda_1 - \lambda_3) = 0, \\
\frac{\partial \mathcal{H}}{\partial u_2} &= 2Bu_2 + \frac{\beta SpI^2}{\{1 + (1 - u_2)pI\}^2}(\lambda_2 - \lambda_1) \\
&\quad + \frac{\beta' VpI^2}{\{1 + (1 - u_2)pI\}^2}(\lambda_2 - \lambda_3) = 0.
\end{aligned} \tag{38}$$

<sup>289</sup> Solving (38) these for optimal control, we obtain

$$\begin{aligned}
u_1^*(t) &= \frac{(\lambda_3 - \lambda_1)\theta S}{2A}, \\
u_2^*(t) &= \frac{(\lambda_1 - \lambda_2)K - (\lambda_2 - \lambda_3)K'}{2B},
\end{aligned} \tag{39}$$

<sup>290</sup> where,

$$K = \frac{\beta SpI^2}{\{1 + (1 - u_2)pI\}^2}, \quad K' = \frac{\beta' VpI^2}{\{1 + (1 - u_2)pI\}^2}.$$

<sup>291</sup> Since the standard control is bounded, we conclude for the control  $u_1(t)$ ,  $u_2(t)$ :

$$u_1^*(t) = \begin{cases} 0, & \frac{(\lambda_3 - \lambda_1)\theta S}{2A} < 0, \\ \frac{(\lambda_3 - \lambda_1)\theta S}{2A}, & 0 < \frac{(\lambda_3 - \lambda_1)\theta S}{2A} < 1, \\ 1, & \frac{(\lambda_3 - \lambda_1)\theta S}{2A} > 1. \end{cases} \tag{40}$$

$$u_2^*(t) = \begin{cases} 0, & \frac{(\lambda_1 - \lambda_2)K - (\lambda_2 - \lambda_3)K'}{2B} < 0, \\ \frac{(\lambda_1 - \lambda_2)K - (\lambda_2 - \lambda_3)K'}{2B}, & 0 < \frac{(\lambda_1 - \lambda_2)K - (\lambda_2 - \lambda_3)K'}{2B} < 1, \\ 1, & \frac{(\lambda_1 - \lambda_2)K - (\lambda_2 - \lambda_3)K'}{2B} > 1. \end{cases} \tag{41}$$

<sup>292</sup> Hence the compact form of  $u_1^*(t)$  is

$$u_1^*(t) = \max \left( \min \left( 1, \frac{(\lambda_3 - \lambda_1)\theta S}{2A} \right), 0 \right).$$

<sup>293</sup> Similarly, we can obtain the compact form of  $u_2^*(t)$  in the form of.

$$u_2^*(t) = \max \left( \min \left( 1, \frac{(\lambda_1 - \lambda_2)K - (\lambda_2 - \lambda_3)K'}{2B} \right), 0 \right).$$

<sup>294</sup> Utilizing the equation and taking the state system along with the adjoint system,  
<sup>295</sup> and the transversality conditions, we have the following optimal system:

$$\begin{aligned}
\frac{dS}{dt} &= \Lambda + \omega V - \frac{\beta SI}{\{1 + (1 - u_2)pI\}} - \{\mu + (1 - u_1)\theta\}S, \\
\frac{dI}{dt} &= \frac{\beta SI}{\{1 + (1 - u_2)pI\}} + \frac{\beta' VI}{\{1 + (1 - u_2)pI\}} - (\mu + \alpha)I, \\
\frac{dV}{dt} &= (1 - u_1)\theta S - (\mu + \omega)V - \frac{\beta' VI}{\{1 + (1 - u_2)pI\}}, \\
\frac{dR}{dt} &= \alpha I - \mu R, \\
\frac{d\lambda_1}{dt} &= - \left[ \frac{\beta I}{\{1 + (1 - u_2)pI\}}(\lambda_2 - \lambda_1) - \lambda_1\{\mu + (1 - u_1)\theta\} + \lambda_3(1 - u_1)\theta \right], \\
\frac{d\lambda_2}{dt} &= - \left[ 2CI + \frac{\beta S}{\{1 + (1 - u_2)pI\}^2}(\lambda_2 - \lambda_1) + \frac{\beta' V}{\{1 + (1 - u_2)pI\}^2}(\lambda_2 - \lambda_3) - \lambda_2(\mu + \alpha) + \lambda_4(\alpha) \right], \\
\frac{d\lambda_3}{dt} &= - \left[ \lambda_1\omega + \frac{\beta' I}{\{1 + (1 - u_2)pI\}}(\lambda_2 - \lambda_3) - \lambda_3(\mu + \omega) \right], \\
\frac{d\lambda_4}{dt} &= - [\lambda_4(-\mu)]. \tag{42}
\end{aligned}$$

<sup>296</sup> with the initial conditions as:  $S(0) > 0$ ,  $I(0) > 0$ ,  $V(0) > 0$ ,  $R(0) > 0$ . and  
<sup>297</sup> boundary conditions as:  $\lambda_i(t_f) = 0$ ,  $i = 1, 2, 3, 4$ .

## <sup>298</sup> 8 Conclusion

<sup>299</sup> In this study, we focused on the role during Zika-virus-Infection in our investi-  
<sup>300</sup> gation. Furthermore, a deterministic SEIVR Zika epidemic model is created,  
<sup>301</sup> investigated, and analysed, utilising nonlinear stability and optimal control the-  
<sup>302</sup> ory. Hier, the proposed model's positivity and boundedness are examined. Using  
<sup>303</sup> a next-generation matrix approach, we were able to determine the fundamental  
<sup>304</sup> reproduction number. The steady-state analysis demonstrates that, if the ba-  
<sup>305</sup> sic reproduction number  $R'_0$  is smaller than unity, the disease-free equilibrium  
<sup>306</sup> (DFE) is globally asymptotically stable. Endemic equilibrium is locally asymp-  
<sup>307</sup> totically stable, if the fundamental reproduction number  $R'_0$  is bigger than 1.  
<sup>308</sup> It is a requirement that the reproduction number be fewer than one, in order  
<sup>309</sup> to eradicate the zikavirus from the populace. Of course, we cannot take into  
<sup>310</sup> account all such considerations in order to avoid complexity. However, we plan  
<sup>311</sup> to consider these options in our future work.

## <sup>312</sup> References

- <sup>313</sup> [1] D Aldila, K Rasyiqah, G Ardanewari, and H Tasman. A mathematical  
<sup>314</sup> model of zika disease by considering transition from the asymptomatic to  
<sup>315</sup> symptomatic phase. In *Journal of Physics: Conference Series*, volume  
<sup>316</sup> 1821, page 012001. IOP Publishing, 2021.

- 317 [2] Aatif Ali, Saeed Islam, M Riaz Khan, Saim Rasheed, FM Allehiany, Jamel  
318 Baili, Muhammad Altaf Khan, and Hijaz Ahmad. Dynamics of a frac-  
319 tional order zika virus model with mutant. *Alexandria Engineering Journal*,  
320 61(6):4821–4836, 2022.
- 321 [3] Ebraheem O Alzahrani, Wisal Ahmad, Muhammad Altaf Khan, and  
322 Sharaf J Malebary. Optimal control strategies of zika virus model with  
323 mutant. *Communications in Nonlinear Science and Numerical Simulation*,  
324 93:105532, 2021.
- 325 [4] Veronika Bernhauerová, Veronica V Rezelj, and Marco Vignuzzi. Modelling  
326 degradation and replication kinetics of the zika virus in vitro infection.  
327 *Viruses*, 12(5):547, 2020.
- 328 [5] Sudhanshu Kumar Biswas, Uttam Ghosh, and Susmita Sarkar. Mathe-  
329 matical model of zika virus dynamics with vector control and sensitivity  
330 analysis. *Infectious Disease Modelling*, 5:23–41, 2020.
- 331 [6] Ebenezer Bonyah, Muhammad Altaf Khan, Kazeem Oare Okosun, and  
332 JF Gómez-Aguilar. On the co-infection of dengue fever and zika virus.  
333 *Optimal Control Applications and Methods*, 40(3):394–421, 2019.
- 334 [7] Renata Gois de Mello, Thaissa Consoni Bernardino, Luis Giovani Oliveira  
335 Guardalini, Renato Mancini Astray, Marta Maria Antoniazzi, Simone  
336 Gonçalves Silva Jared, Eutimio Gustavo Fernández Núñez, and Soraia At-  
337 tie Calil Jorge. Zika virus-like particles (vlps) produced in insect cells.  
338 *Frontiers in Pharmacology*, 14:1181566, 2023.
- 339 [8] Wendell H Fleming and Raymond W Rishel. *Deterministic and stochastic*  
340 *optimal control*, volume 1. Springer Science & Business Media, 2012.
- 341 [9] Gilberto González-Parra, Miguel Díaz-Rodríguez, and Abraham J Arenas.  
342 Optimization of the controls against the spread of zika virus in populations.  
343 *Computation*, 8(3):76, 2020.
- 344 [10] Jane M Heffernan, Robert J Smith, and Lindi M Wahl. Perspectives on the  
345 basic reproductive ratio. *Journal of the Royal Society Interface*, 2(4):281–  
346 293, 2005.
- 347 [11] MA Khan, Syed Wasim Shah, Saif Ullah, and JF Gómez-Aguilar. A dy-  
348 namical model of asymptomatic carrier zika virus with optimal control  
349 strategies. *Nonlinear Analysis: Real World Applications*, 50:144–170, 2019.
- 350 [12] Kumpati S Narendra and Robert Shorten. Hurwitz stability of metzler ma-  
351 trices. *IEEE Transactions on Automatic Control*, 55(6):1484–1487, 2010.
- 352 [13] Rhoda Nwalozie, Roseanne Adah Ikpeama, Brenda Anyakwe Nnokam, and  
353 Rose Mary Kaiso Esiere. A review on zika virus: Epidemiology, patho-  
354 genesis and clinical outcomes. *International Journal of Pathogen Research*,  
355 12(3):35–41, 2023.

- 356 [14] Lev Semenovich Pontryagin. *Mathematical theory of optimal processes*.  
357 CRC press, 1987.
- 358 [15] Shahram Rezapour, Hakimeh Mohammadi, and Amin Jajarmi. A new  
359 mathematical model for zika virus transmission. *Advances in difference*  
360 *equations*, 2020(1):1–15, 2020.
- 361 [16] Naveen Sharma, Ram Singh, Jagdev Singh, and Oscar Castillo. Modeling  
362 assumptions, optimal control strategies and mitigation through vaccination  
363 to zika virus. *Chaos, Solitons & Fractals*, 150:111137, 2021.
- 364 [17] Pauline Van den Driessche and James Watmough. Reproduction numbers  
365 and sub-threshold endemic equilibria for compartmental models of disease  
366 transmission. *Mathematical biosciences*, 180(1-2):29–48, 2002.
- 367 [18] Xia Wang, Mingwang Shen, Yanni Xiao, and Libin Rong. Optimal control  
368 and cost-effectiveness analysis of a zika virus infection model with com-  
369 pre-  
370 hensive interventions. *Applied Mathematics and Computation*, 359:165–185,  
2019.